Rheumatoid Arthritis Pain Reduction Therapy
RHEUMATOID ARTHRITIS PAIN REDUCTION - PEMF PULSED ELECTROMAGNETIC FIELD
Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting over 1.3 million Americans, and as much as 1% of the population worldwide (1). Although RA predominantly affects large and small joints, it can affect other organs in the body, including those of the cardiovascular, pulmonary, and ophthalmologic systems (2). The pathophysiology of RA includes abnormal activation of blood cells, namely macrophages, T-cells, and B-cells, which produce pro-inflammatory mediators (e.g., cytokines and growth factors) that initiate an inflammatory cascade that leads to joint damage (i.e., bone erosions) and systemic complications (3). Current treatments include corticosteroids, traditional disease-modifying antirheumatic drugs (DMARDs), and anti-cytokines (biologics); however, these drugs have adverse effects which can be severe, including osteoporosis, alterations of metabolism, infection, bone marrow suppression, hepatitis, and an increased risk of malignancies (4–6). As the disease progresses, joints are damaged resulting in impaired range of motion, joint deformity, and dysfunction (7). Although the currently approved drugs are known to prevent further joint damage, the effect of these drugs in repairing bone erosions has yet to be demonstrated, and pro-anabolic agents are needed to promote bone formation at the erosion sites (8). Therefore, innovative and safe strategies aimed at both reducing inflammation and promoting tissue regeneration are urgently needed to inhibit the progression of RA.
By inducing a mild electrical magnetic current into damaged cells, PEMF therapy slows or stops the release of pain and inflammatory mediators, increases blood flow of the cells, and re-establishes normal cell interaction. With reduced inflammation, pain decreases, energy increases, and faster tissue healing occurs.
IT'S NOT MAGIC, IT'S SCIENCE
Study on Rheumatoid Arthritis Pain Reduction Therapy:
Conclusions. PEMF exposure in refractory CTS provides statistically significant short- and long-term pain reduction and mild improvement in objective neuronal functions. Neuromodulation appears to influence nociceptive-C and large A-fiber functions, probably through ion/ligand binding.